Dongliang Xu

机构：Shanghai University of Traditional Chinese Medicine, Shuguang Hospital · ORCID：0000-0001-8941-3802

发表论文 21 篇 · 总被引 144 次 · h-index 8

代表论文

• TLimmuno2: predicting MHC class II antigen immunogenicity through transfer learning (2023 · Briefings in Bioinformatics · 被引 24)
• PIGT promotes cell growth, glycolysis, and metastasis in bladder cancer by modulating GLUT1 glycosylation and membrane trafficking (2024 · Journal of Translational Medicine · 被引 22)
• Identification of the novel therapeutic targets and biomarkers associated of prostate cancer with cancer-associated fibroblasts (CAFs) (2023 · Frontiers in Oncology · 被引 18)
• Global burden of bladder cancer attributable to smoking in 204 countries and territories, 1990–2019 (2024 · Heliyon · 被引 15)
• Programmed Cell Death in Cancer (2025 · MedComm · 被引 12)
• Ezetimibe Engineered L14‐8 Suppresses Advanced Prostate Cancer by Activating PLK1/TP53‐ SAT1 ‐Induced Ferroptosis (2025 · Advanced Science · 被引 8)